Navigation Links
EpiVax Launches Precision Cancer Immunotherapy Venture, EpiVax Oncology
Date:9/25/2017

PROVIDENCE, R.I., Sept. 25, 2017 /PRNewswire/ -- EpiVax, Inc., a leader in the fields of immunogenicity assessment, vaccine design, and immune-engineering today announced the launch of EpiVax Oncology Inc., a company focused on the development of personalized therapeutic cancer vaccines. EpiVax has provided $500,000 in seed funding and has provided exclusive access to enabling technologies to the new precision immunotherapy venture. Gad Berdugo MSc Eng., MBA will lead EpiVax Oncology as Chief Executive Officer. Gad brings over 25 years of biotechnology operational, strategic partnering and financial experience gained at Abbott, Baxter, and Lazard, as well as emerging cancer biotechnology companies.

EpiVax Oncology's approach to precision immunotherapy is based on mutated, tumor-specific epitopes, termed Neo-Epitopes, which generate highly potent specific T cell responses against a wide range of tumor types. The company uses genetic profiling (via NGS sequencing) to generate therapeutic vaccines customized for each cancer patient's unique tumor load. EpiVax Oncology vaccines can be used in combination with checkpoint inhibitors or potentially as single agents.

EpiVax Oncology's key competitive advantage is centered on a streamlined, validated, commercial-grade Neo-Epitope in silico discovery platform called Ancer™. The Ancer™ platform is powered by EpiVax's EpiMatrix™ and JanusMatrix™ predictive algorithms and exclusively licensed to EpiVax Oncology for the field of cancer. Ancer™ identifies highly immunogenic, Class I and Class II, CD4 and CD8, T cell Neo-Epitopes while selecting out Treg-like epitopes. Candidate Neo-epitopes are qualified and ranked using a proprietary process designed to strengthen vaccine efficacy and decrease the incidence of immune-related adverse events. In head-to-head comparisons, Ancer™ is significantly better at Neo-Epitope identification than public or academic platforms.

"Ancer™ is setting EpiVax Oncology apart from emerging companies such as Neon Therapeutics, Gritstone Oncology and BioNtech. EpiVax Oncology will leverage EpiVax's world class excellence in computational immunology, genomics and vaccine design, built over the last 20 years, to create safe, effective, and affordable immunotherapies. We are committed to delivering on the promise of precision medicine," said Gad Berdugo.

CLINICAL DEVELOPMENT: EpiVax Oncology is initially preparing for Phase 1b clinical trials in bladder cancer and melanoma using Ancer™-derived Neo-Epitopes formulated in a proprietary clinically-tested delivery vehicle. The first trials are planned to start in 2018.

CAPITAL RAISE: EpiVax Oncology is a fully independent company currently conducting a $2M bridge capital raise to prepare for an IND as well as a $10M to $25M Series A financing to fund the first-in-man clinical trials.

ABOUT EPIVAX: EpiVax, Inc. is a privately-held biotechnology company focused on the development of vaccines and immunotherapies mainly for infectious diseases and autoimmunity. Led by Annie S. De Groot, M.D., an internationally recognized vaccine design thought leader, and William Martin, chief architect of the EpiMatrix Epitope Discovery Platform, EpiVax has enjoyed significant success in the fields of immunology and bioinformatics.

http://www.EpiVax.com
http://www.EpiVaxOnco.com

Media Contacts:
Gad Berdugo
EpiVax Oncology
gberdugo@epivaxonco.com
+1 (646) 912-2525

Anne S. De Groot MD
EpiVax
AnnieD@EpiVax.com
+1 (401) 952-4227

View original content with multimedia:http://www.prnewswire.com/news-releases/epivax-launches-precision-cancer-immunotherapy-venture-epivax-oncology-300525002.html


'/>"/>
SOURCE EpiVax, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. EpiVax Reports $5.2 Million for New Q Fever Vaccine Means There is Hope for Vaccines On Demand
2. EpiVax: Investition von 5,2 Millionen $ in neuen Impfstoff für Q-Fieber bedeutet Hoffnung für Impfstoffe auf Abruf
3. $5.8 Million Awarded For Vaccine Engineering Will Use "Immune History" To Protect Against Bird Flu, A Collaboration Led By EpiVax
4. X-Change Corporation Launches Upgraded Version of Phytiva Website, As Company Targets Distribution of Phytiva Product Line in United States and Worldwide, Extracts and New Products in Europe
5. PENTAX Medical Launches Industrys Highest* Resolution HD+ Imaging Technology For Flexible Endoscopy
6. Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices
7. Research-based Pharmaceutical Industry Launches Do You Mind? Campaign to Fight Mental and Neurological Disorders
8. WomanCare Global launches Simplant, Long-acting Reversible Contraception, in Chile
9. Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site
10. Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services
11. TMA Launches Physician Services Organization for Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2018)... , ... December 04, 2018 , ... The inaugural Steven ... and CEO of Virginia Mason Health System in Seattle, Washington, at The Leapfrog ... created by Costs of Care , a leading non-profit dedicated to curating and ...
(Date:12/5/2018)... ... December 05, 2018 , ... Medical ... , **An FDAnews Webinar**, Tuesday, Dec. 18, 2018, 1:30 p.m. - 3:00 ... vulnerable they become. , Cybersecurity is becoming an everyday risk. , FDAnews ...
(Date:12/5/2018)... ... December 05, 2018 , ... Two women with a vision to make ... Award. , Jean Bennett, M.D., Ph.D., and Katherine A. High, M.D., whose work ... on Dec. 4 at Sanford Health, headquartered in Sioux Falls, South Dakota. , ...
Breaking Medicine Technology:
(Date:12/10/2018)... , ... December 10, 2018 , ... Loma Linda University ... major freight railyards in California and found a link with freight-railyard pollution to asthma-related ... Medicine Reports. , This large-scale railyard study is a follow-up to the ...
(Date:12/10/2018)... ... December 10, 2018 , ... Florida Hospital, soon to be ... Chapel recently received the 2018 Press Ganey Guardian of Excellence Award® for achieving ... emergency and inpatient services is measured through random, voluntary patient surveys and the ...
(Date:12/8/2018)... (PRWEB) , ... December 07, 2018 , ... ... , At this critical juncture in world affairs, U.S. leadership and funding at ... relationship over the years—great strides in reducing extreme poverty and advancing global health ...
(Date:12/6/2018)... ... December 06, 2018 , ... HMP, ... Post-Acute Care Symposium (PACS). The meeting will take place May 9–10, 2019, and ... Society meeting in San Antonio, Texas. , PACS is uniquely designed to provide ...
(Date:12/6/2018)... DIEGO (PRWEB) , ... December 06, 2018 , ... ... Mike Wilson, Medicare Analytic Consultant Senior of Blue Cross and Blue Shield of ... are Interrelated” on Tuesday, December 11, 2018 at 2:15pm PT at the Fairmont ...
Breaking Medicine News(10 mins):